(Q35048648)

6 August 2017

title

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration (English)

1 reference

6 August 2017

0 references

1

Frank G Holz

1 reference

6 August 2017

7

Carel B Hoyng

1 reference

6 August 2017

Ramin Tadayoni

2

1 reference

6 August 2017

Stephen Beatty

3

1 reference

6 August 2017

Alan Berger

4

1 reference

6 August 2017

Matteo G Cereda

5

1 reference

6 August 2017

Rafael Cortez

6

1 reference

6 August 2017

Philip Hykin

8

1 reference

6 August 2017

Giovanni Staurenghi

9

1 reference

6 August 2017

Stephanie Heldner

10

1 reference

6 August 2017

Timon Bogumil

11

1 reference

6 August 2017

Theresa Heah

12

1 reference

6 August 2017

Sobha Sivaprasad

13

1 reference

6 August 2017

language of work or name

English

0 references

publication date

5 September 2014

1 reference

British Journal of Ophthalmology

6 August 2017

published in

1 reference

6 August 2017

volume

99

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

220-226

1 reference

Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316940

Mechanisms of age-related macular degeneration

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316940

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316940

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316940

Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316940

Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316940

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316940

Ranibizumab for neovascular age-related macular degeneration

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316940

Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4316940

A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact

8 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305327

Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305327

Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305327

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2

21 January 2018

1 reference

12 December 2020

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

1 reference

12 December 2020

Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study

1 reference

12 December 2020

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study

1 reference

12 December 2020

A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration

1 reference

12 December 2020

Versorgung von älteren Menschen mit neovaskulärer altersabhängiger Makuladegeneration

1 reference

12 December 2020

10.1136/BJOPHTHALMOL-2014-305327

Identifiers

DOI

1 reference

6 August 2017

1 reference

6 August 2017

1 reference